{"description":"Only the following adverse events were records: mucositis, febrile neutropenia, pain, xerostomia, feeding tube placement, and neuropathy which was deemed pertinent to the comparision of regimens in this setting.","eventGroups":[{"description":"Patients receive induction chemotherapy comprising docetaxel, cisplatin, and fluorouracil. Treatment repeats every 21 days for 3 courses. Patients achieving a pathologic complete response at the primary site and a clinical complete response in the neck then receive carboplatin once weekly and undergo concurrent radiotherapy once daily, 5 days a week, for 7 weeks. Patients with a partial response at the primary site (i.e., positive biopsy), stable disease, or radiographic evidence of persistent disease in the neck receive docetaxel once weekly for 4 weeks and undergo concurrent radiotherapy once or twice daily, 5 days a week, for 6 weeks.\n\ncisplatin : Given IV\n\nradiation therapy : Patients undergo radiation therapy once or twice daily, 5 days a week, for up to 7 weeks\n\ncarboplatin : Given IV\n\nfluorouracil : Given IV\n\ndocetaxel : Given IV","id":"EG000","otherNumAffected":70,"otherNumAtRisk":70,"seriousNumAffected":56,"seriousNumAtRisk":70,"title":"Arm I"},{"description":"Patients receive cisplatin IV on weeks 1 and 4 and undergo concurrent radiotherapy once or twice daily, 5 days a week, for 6 weeks.\n\ncisplatin : Given IV\n\nradiation therapy : Patients undergo radiation therapy once or twice daily, 5 days a week, for up to 7 weeks","id":"EG001","otherNumAffected":75,"otherNumAtRisk":75,"seriousNumAffected":29,"seriousNumAtRisk":75,"title":"Arm II"}],"frequencyThreshold":"5","otherEvents":[{"organSystem":"Gastrointestinal disorders","stats":[{"groupId":"EG000","numAffected":29,"numAtRisk":70},{"groupId":"EG001","numAffected":44,"numAtRisk":75}],"term":"Mucositis"},{"organSystem":"General disorders","stats":[{"groupId":"EG000","numAffected":41,"numAtRisk":70},{"groupId":"EG001","numAffected":35,"numAtRisk":75}],"term":"Pain"},{"organSystem":"Gastrointestinal disorders","stats":[{"groupId":"EG000","numAffected":42,"numAtRisk":70},{"groupId":"EG001","numAffected":46,"numAtRisk":75}],"term":"Xerostomia"},{"organSystem":"Immune system disorders","stats":[{"groupId":"EG000","numAffected":22,"numAtRisk":70},{"groupId":"EG001","numAffected":18,"numAtRisk":75}],"term":"Neuropathy"}],"seriousEvents":[{"organSystem":"Gastrointestinal disorders","stats":[{"groupId":"EG000","numAffected":33,"numAtRisk":70},{"groupId":"EG001","numAffected":12,"numAtRisk":75}],"term":"Mucositis"},{"organSystem":"Blood and lymphatic system disorders","stats":[{"groupId":"EG000","numAffected":16,"numAtRisk":70},{"groupId":"EG001","numAffected":1,"numAtRisk":75}],"term":"Febrile Neutropenia"},{"organSystem":"General disorders","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":70},{"groupId":"EG001","numAffected":9,"numAtRisk":75}],"term":"Pain"},{"organSystem":"Gastrointestinal disorders","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":70},{"groupId":"EG001","numAffected":5,"numAtRisk":75}],"term":"Xerostomia"},{"organSystem":"Nervous system disorders","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":70},{"groupId":"EG001","numAffected":2,"numAtRisk":75}],"term":"Neurpathy"}]}